Turn Therapeutics Files S-1 for GEM Share Sales, Eyes Drug Approvals

TL;DR

Turn Therapeutics is burning cash to pivot from medical devices to drug development, and while GEM is funding them, this S-1 is just selling stockholders cashing out, so don't expect a pop.

AI Summary

Turn Therapeutics Inc. (TTRX) filed an S-1 on October 9, 2025, for the offer and sale of up to 7,000,000 shares of common stock by selling stockholders GEM Global Yield LLC SCS and GEM Yield Bahamas Limited. The company will not receive any proceeds from these sales. TTRX's common stock commenced trading on the Nasdaq Global Market on October 8, 2025, at a closing price of $7.00 per share. The company has a committed equity financing agreement with GEM for up to $85,000,000, and issued a warrant to GEM for 1,192,207 shares at an exercise price of $5.03 per share on the Listing Date. Turn Therapeutics, an emerging growth company and smaller reporting company, is a pharmaceutical and medical device development company focused on its proprietary PermaFusion platform, which enhances drug performance by enabling stable suspension of water-soluble APIs in oil-based carriers without emulsifiers. Their primary development programs target dermatological diseases like eczema and onychomycosis, utilizing their Hexagen formula, which has received three FDA 510(k) clearances (K160872, K171191, K183681). The company is transitioning from medical device sales to drug development, specifically seeking FDA drug approval for GX-03/Hexagen (containing polyhexanide or PHMB) for eczema and onychomycosis, and is also exploring intranasal vaccines and preclinical studies for herpes zoster ophthalmicus and basal cell carcinoma.

Why It Matters

This S-1 filing signals Turn Therapeutics' strategic pivot from medical device distribution to drug development, a higher-risk, higher-reward endeavor for investors. The committed equity financing of up to $85,000,000 from GEM provides crucial capital for clinical trials, but the immediate offering by selling stockholders means no direct cash infusion for the company from this specific share sale. For employees, this shift could mean a focus on R&D roles, while customers might see new drug products for eczema and onychomycosis in the future, potentially disrupting existing treatments. Competitively, if their PermaFusion platform proves effective in drug applications, it could challenge established dermatology and vaccine players.

Risk Assessment

Risk Level: high — The company is not currently generating revenue from its core medical devices, having voluntarily ceased internal wound care sales in 2019 to pursue new drug approvals. This indicates a significant reliance on future drug development success, which is inherently risky. Furthermore, the S-1 explicitly states, "Investing in our common stock involves risks," and highlights that the founder controls more than 50% of outstanding shares, creating potential conflicts of interest.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence on Turn Therapeutics' drug development pipeline and clinical trial progress. Given the company is not receiving proceeds from this specific offering and has ceased revenue-generating activities for its medical devices, it's a speculative play on future drug approvals. Monitor future filings for updates on clinical trials and actual revenue generation.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Executive Compensation

Key Numbers

• $85,000,000 — Aggregate purchase price (Committed equity financing from GEM under the GEM Purchase Agreement)
• 7,000,000 — Shares of common stock (Maximum number of shares offered by selling stockholders in this S-1)
• $7.00 — Closing price per share (Closing price of TTRX common stock on Nasdaq on October 8, 2025)
• 1,192,207 — Shares underlying GEM Warrant (Number of shares GEM can purchase via warrant issued on October 8, 2025)
• $5.03 — Exercise price per share (Exercise price for the GEM Warrant)
• 4.0% — Percentage of total outstanding equity (Equity interest represented by the GEM Warrant on a fully diluted basis)
• 1% — Commitment fee percentage (Commitment fee paid to GEM based on the aggregate limit of $85,000,000)
• 2019 — Year (Year Turn Therapeutics voluntarily ceased internal wound care sales to pursue drug development)
• 85% — Reduction in viral load (Observed in preclinical in-vivo xenograft studies for herpes zoster ophthalmicus)
• 29% — Comparative reduction in tumor size (Observed for Hexagen formula compared to placebo in basal cell carcinoma xenograft study)

Key Players & Entities

• Turn Therapeutics Inc. (company) — Registrant and issuer of common stock
• GEM Global Yield LLC SCS (company) — Selling stockholder and committed equity financing partner
• GEM Yield Bahamas Limited (company) — Selling stockholder
• Nasdaq Global Market (regulator) — Exchange where TTRX common stock is listed
• Bradley Burnam (person) — Chief Executive Officer and founder, controlling over 50% of shares
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Davis Polk & Wardwell LLP (company) — Legal counsel for the company
• MiMedx Group, Inc. (company) — Licensee of the FleX Product medical device formulation
• McKesson (company) — Former commercial distributor of Hexagen for wound care
• Polyhexanide (PHMB) (other) — Active pharmaceutical ingredient in GX-03/Hexagen

FAQ

Risk Factors

• Reliance on GEM Financing [high — financial]: The company has a committed equity financing agreement with GEM Global Yield LLC SCS for up to $85,000,000. While this provides potential capital, the company's ability to draw down funds is subject to various conditions, and the issuance of shares at potentially fluctuating market prices could dilute existing shareholders.
• FDA Approval Uncertainty [high — regulatory]: Turn Therapeutics is seeking FDA drug approval for GX-03/Hexagen for eczema and onychomycosis. The drug development process is lengthy, expensive, and uncertain, with no guarantee of successful approval or commercialization.
• Transition to Drug Development [medium — operational]: The company is transitioning from medical device sales to drug development, having voluntarily ceased internal wound care sales in 2019. This shift involves significant new risks and requires substantial investment in research and development.
• Competition in Dermatological Market [medium — market]: The markets for eczema and onychomycosis treatments are competitive, with established players and numerous therapies available. Turn Therapeutics will face challenges in gaining market share and achieving commercial success.
• Limited Operating History and Profitability [medium — financial]: As an emerging growth company, Turn Therapeutics has a limited operating history and has not yet achieved profitability. Its future financial performance is highly dependent on the success of its drug development programs.
• Reliance on 510(k) Clearances [low — regulatory]: While the Hexagen formula has received three FDA 510(k) clearances for medical devices, these clearances do not guarantee approval for drug applications. The regulatory pathway for drugs is distinct and more rigorous.

Industry Context

Turn Therapeutics operates in the highly competitive pharmaceutical and medical device sector, specifically targeting dermatological diseases. The market for treatments for conditions like eczema and onychomycosis is substantial but crowded with established therapies. The company's strategy to leverage its PermaFusion platform for drug delivery aims to differentiate its offerings, but success hinges on navigating the rigorous FDA drug approval process and competing against both generic and innovative treatments.

Regulatory Implications

The company faces significant regulatory hurdles related to drug development. While its Hexagen formula has received FDA 510(k) clearances for medical devices, obtaining drug approval for GX-03/Hexagen will require extensive clinical trials and adherence to stringent FDA guidelines. Any delays or failures in the drug approval process represent a major risk.

What Investors Should Do

1. Monitor FDA Approval Progress
2. Analyze GEM Financing Terms
3. Evaluate Competitive Landscape
4. Scrutinize Preclinical Data

Key Dates

• 2025-10-09: S-1 Filing — Initiated the process for selling stockholders to offer up to 7,000,000 shares of common stock.
• 2025-10-08: Common Stock Commenced Trading on Nasdaq — Marked the public trading debut of TTRX, with a closing price of $7.00 per share, and the issuance of a warrant to GEM.
• 2025-10-08: GEM Warrant Issued — GEM received a warrant for 1,192,207 shares at $5.03 per share, representing a potential 4.0% equity interest.
• 2019-01-01: Voluntary Cessation of Internal Wound Care Sales — Company shifted strategic focus from medical device sales to drug development.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This document provides comprehensive information about the company's business, financial condition, and the securities being offered.)

PermaFusion Platform

Turn Therapeutics' proprietary technology that enables stable suspension of water-soluble APIs in oil-based carriers without emulsifiers. (This is the core technology underlying the company's drug development programs.)

API

Active Pharmaceutical Ingredient, the biologically active component of a drug product. (The effectiveness of Turn Therapeutics' drug candidates depends on the performance of their APIs within the PermaFusion platform.)

FDA 510(k) Clearance

A premarket notification process by the U.S. Food and Drug Administration (FDA) for medical devices that are not substantially equivalent to a legally marketed device. (Indicates that the Hexagen formula has met certain regulatory standards for medical devices, but not for drugs.)

Emerging Growth Company

A company that has total annual gross revenue of less than $1.235 billion during its most recently completed fiscal year. (Allows TTRX to benefit from certain exemptions and reduced disclosure requirements under the JOBS Act.)

Smaller Reporting Company

A company that meets certain criteria related to public float and revenue, allowing for scaled-down disclosure requirements. (Indicates TTRX has fewer reporting obligations compared to larger public companies.)

Committed Equity Financing

An agreement where an investor commits to purchase a certain amount of a company's stock over time, often at market prices or with pre-determined discounts. (Provides TTRX with potential access to capital, but the terms and dilution impact are critical for investors.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) before a certain expiration date. (The warrant issued to GEM represents a potential future dilution of existing shareholders' equity.)

Year-Over-Year Comparison

As this is an S-1 filing related to a stock offering by selling stockholders and not a routine periodic report, a direct comparison of key financial metrics like revenue growth, margin changes, or new risks against a previous filing is not applicable. The S-1 focuses on providing current information for the offering and the company's business as it stands, including the recent commencement of trading on Nasdaq and the committed equity financing.

Key Financial Figures

• $0.0001 — 0,000 shares of common stock, par value $0.0001 per share ("common stock"), of Turn The
• $85,000,000 — k having an aggregate purchase price of $85,000,000 (the "aggregate limit"), pursuant to dr
• $5.03 — ,192,207 shares at an exercise price of $5.03 per share, subject to adjustments provi
• $7.00 — ommon stock, as reported on Nasdaq, was $7.00 per share. We are an "emerging growth

Filing Documents

• tm2524982-2_s1.htm (S-1) — 2270KB
• tm2524982d3_ex4-1.htm (EX-4.1) — 119KB
• tm2524982d3_ex5-1.htm (EX-5.1) — 10KB
• tm2524982d3_ex16-1.htm (EX-16.1) — 3KB
• tm2524982d3_ex23-1.htm (EX-23.1) — 3KB
• tm2524982d2_ex-filingfees.htm (EX-FILING FEES) — 29KB
• fc_roadmap-4clr.jpg (GRAPHIC) — 93KB
• lg_turntherapeutics-4clr.jpg (GRAPHIC) — 24KB
• tm2524982d3_ex16-1img001.jpg (GRAPHIC) — 9KB
• tm2524982d3_ex4-1img001.jpg (GRAPHIC) — 6KB
• tm2524982d3_ex5-1img001.jpg (GRAPHIC) — 1KB
• 0001104659-25-098363.txt ( ) — 2737KB
• tm2524982d2_ex-filingfees_htm.xml (XML) — 7KB

Risk Factors

Risk Factors 22 Special Note Regarding Forward-Looking Statements 57

Use Of Proceeds

Use Of Proceeds 58 Determination of Offering Price 59 Market Information for Common Stock and Dividend Policy 60 Capitalization 61

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 62

Business

Business 72 Management 92 Executive and Director Compensation 96 Certain Relationships and Related Party Transactions 102 Principal Stockholders 104 Committed Equity Financing 107

Description Of Capital Stock

Description Of Capital Stock 109 Material U.S. Federal Income and Estate Tax Consequences to Non-U.S. Holders of Our Common Stock 114 Plan Of Distribution 122 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 124 Legal Matters 124 Experts 124 Where You Can Find More Information 124 Index to Consolidated Financial Statements F-1 In this prospectus, "Turn Therapeutics," "Global Health Solutions," the "Company," "we," "us" and "our" refer to Turn Therapeutics Inc. and its consolidated subsidiaries. In connection with the direct listing of our common stock on Nasdaq (the "direct listing"), we changed our name from Global Health Solutions, Inc. to Turn Therapeutics Inc. Neither we nor the selling stockholders have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared. Neither we nor the selling stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The selling stockholders are offering to sell, and seeking offers to buy, shares of their common stock only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. This prospectus includes industry and market data that we obtained from periodic industry publications, third-party studies and surveys, filings of public companies in our industry and internal company surveys. These sources include government and industry sources. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Alt

View Full Filing

View this S-1 filing on SEC EDGAR